X
Tagrisso on target to be EGFR+ lung cancer standard
https://pharmaphorum.com/news/tagrisso-target-egfr-lung-cancer-standard/
NSCLC
Roche’s Alecensa shows big benefit in brain mets, advanced lung cancer
Roche’s Alecensa has shown strong results in two studies looking at its benefits in ALK positive non-small cell lung cancer (NSCLC) patients, both in first line use and a second line setting.
Evolving immunotherapy strategies in NSCLC
Status of immunotherapies in non-small cell lung cancer (NSCLC).
ASCO 2017: Breast cancer next target for Keytruda
Immunotherapy combinations will be the focus – but attention is shifting towards these agents proving their overall survival benefits.
Novartis’ Zykadia gets fast first-line lung cancer review
Roche rival has Breakthrough Therapy status.
Roche’s Alecensa approved in Europe, with head-to-head data coming
Alecensa part of Roche’s goal of becoming dominant player in NSCLC